Who should attend the AseBio Investor Day?

Investors & Financial Organizations

  • Venture Capital and other private investment platforms
  • Pharmaceutical & Industrial Companies
  • Business Angels & Family Offices
  • Corporate Venture Capital
  • Investment Banks & Financial Services Companies

Innovative Companies & Institutions

  • Executives from innovative biotech companies from all areas of biotechnology (Life Sciences, Agritech, Industrial)
  • Research & Academic Institutions
  • Non-profit organizations
  • Government Organizations

This event is intended for companies actively seeking investment as well as investors looking for funding. Service providers including law, accounting and consulting firms, contract manufacturers, active pharmaceutical ingredient manufacturers, contract research organizations, real estate development companies etc. will be allowed to attend on a one-to-one basis as approved by AseBio. If you are a service company and you’re interested in making use of the partnering system, we have exclusive sponsorship opportunities including this possibility. Please contact us: Stuart Medina–

Previous Edition Investors (2022)

ABBVIE, Germany

At AbbVie, we partner to achieve two important outcomes: to deliver innovative medicines and to make a remarkable impact on people’s lives.

We focus on identifying and evaluating new opportunities that complement and enhance our existing internal innovation strategies. S&E works in close partnership with our R&D and commercial teams, BD&A and Ventures to thoughtfully address each opportunity.


AdBio partners (formerly Advent France Biotechnology) is a venture capital firm investing in early-stage life sciences companies in Europe.

AdBio partners’ unique strategy combines early-stage investments in promising startups and strong entrepreneurial support to enable and strengthen the company’s growth.


Alta Life Sciences is a leading venture capital firm located in Barcelona. Alta LS is stage agnostic and invests in all areas of life sciences including biotechnology, medical devices, diagnostics, genomics and digital health. Its geographical focus is mainly Spain, although it can invest elsewhere. The team is formed by experienced life science professionals from the US and Spain.


Asabys Partners is a venture capital firm from Barcelona investing across the board in human healthcare. We are active in the health-tech and biopharma industries and aim to invest in Spain and abroad in highly innovative and transformative technologies. We are motivated by the idea of pushing the boundaries of science and medicine. We do this through the sourcing and financing of the most disruptive technologies, and through the collaboration with the best internal and external talents of our industry. We have an entrepreneurial spirit and seek to be involved in the building and management of our companies. Not just investors, we consider ourselves as partners and collaborators to our portfolio companies.


AurorA Science is the result of the partnership between the technology transfer company AurorA-TT and two strategic industrial partners and investors, Rottapharm Biotech and Italfarmaco, who share in-house R&D facilities and expertise to support the development of portfolio companies and create the ideal conditions for partnering with bio-pharma companies.

Investment size will vary in a range of €1 to 5M per deal to support the final pre-clinical activities and the early clinical developments.


We invest in Seed and Early Stage in the Industrial Deep Science sector with the goal of transferring to society the technologies born in academic and research institutions in Spain and providing support for transforming breakthrough discoveries into products through start-ups.

We focus on Deep Science and Technology Transfer and build close ties with universities, research centers, technology transfer offices, and industrial companies to discover new promising projects. The selection process involves the evaluation of scientific research, intellectual property, competitive technologies both from a scientific and marketing perspective.

Disruptive Technologies with sustainable competitive advantages based on the company’s Intellectual Property and know-how and high added value. We focus on technologies that fulfill non-covered needs on high growth markets.

We invest in Science-based companies focused on: New Space, New Energy, New Materials, Agro & Food, Environment, Healthcare & Wellbeing, Medtech, Robotics & AI.


BHV Partners is a firm focused on identifying top academic research projects that are contributing solutions to global health challenges, guiding the scientist-entrepreneur in starting up a company, accelerating its growth and opening doors from seed to series-B investment.

Our network of renowned advisors, strategic alliances and senior executive team, committed to operational excellence, guarantee quality service for scientists-entrepreneurs, investors and corporate ventures, and technology transfer offices.

Located in Barcelona and in Silicon Valley, two of the most dynamic healthcare and life sciences ecosystems in the world.


Bioknostic is a holding company specialised in investing in companies in the biotechnology sector with more than 25 years of experience.  We have a multidisciplinary team with transversal skills that studies projects in their initial stages of business and proceeds to invest as seed capital in those that we consider to have a future and in which we can provide a differential value.


Bionova Capital is an independent, healthcare-specialized venture capital firm, investing in early-stage life science companies.
Bionova Capital was founded in 2015 and was formerly known as Hovione Capital.

BME - Growth Market, Spain

BME Growth is the market for BME’s SMEs. It is a platform that allows growing small and medium-sized companies to access the capital markets.

At this moment, 129 companies are listed in BME Growth who have raised more than € 5,662 million since its creation.

During the last years, the trading volume of companies in BME Growth has increased by 307%, which represents a compound annual rate of 42.05%, reaching € 1,000 million in 2021.

Entorno Pre Mercado is a special ecosystem created by BME with investors and market professionals for training and networking for those companies who are interested in financing growth via stock markets.


Caixa Capital Risc is the venture capital arm of CriteriaCaixa which invests in innovative companies in their start-up and growth stages. The company has three specialised teams in the areas of Information Technology, Life Sciences, and Industrial technologies.

Caixa Capital Risc currently manages more than 200 million Euro through 9 specialised vehicles.


Capital Cell is the first pan-European crowdinvesting platform for biotech & Life Sciences companies.

Mixing VC, business angels, accredited investors and the power of the Crowd, we are building a global meeting point for companies and researchers working, fostering and financing tomorrow’s medical science.

In this health & biotech marketplace, global investors of any size can invest in non-listed companies via equity-crowdfunding with the most accurate scientific and financial information about every project.


Currently, the INNVIERTE program fosters the entry of private capital into Spanish technological firms in market conditions, in order to support their technological activities, provide them with management skills and internationalization, and market knowledge. To this end, it aims to promote public-private venture capital investments that meet the following criteria:

  • Investments involve taking temporary shares in the capital of target firms;
  • Investments are financed by more than 50% by private investors;
  • Investment decisions will be taken on a commercial basis and will aim at making profits;
  • The management of investments and divestments will be performed by professionals from the private sector with experience in the corresponding technology sector in Spain;
  • Private investors will assume leadership in the transactions needed to implement investments and divestments;
  • The risks and benefits of each investment will be shared with the private investor in strict equality of rights and obligations, in proportion to their respective contributions.

INNVIERTE is attracting potential private investors which provide market and technology knowledge, opportunities to access new customers, and opportunities for internationalization.

These private investors aggregated in equity vehicles are selected through an open, objective, transparent, and competitive public process, given the interest of CDTI in having the largest number of candidates with the maximum capacity, experience, and knowledge in their respective sectors.

With each of these equity vehicles, the INNVIERTE program articulates appropriate investment instruments to meet the financing needs of companies and mitigate market failures identified in technological sectors which are traditionally forgotten by specialized investors.


Checkpoint Partners is a Madrid based specialist corporate finance company specialized on providing financial advice to emerging technology companies. “Committed on growing to become a leading European (with an eye in Latin America) Investment Banking actor in life sciences, energy technology and ICT”.


Clave Mayor is a venture capital firm, focused in tech transfer projects mainly in Spain. We manage currently several funds in investment process with a total volume of more than 30 million euros to invest in different sectors, one of which is Health, counting on not only biotech projects but also and more precisely, Applied Technologies Spinoffs/Startups referred to Medical Devices, mHealth, e-Health…

Our purpose is to invest after the Proof of Concept (TRLs 4-9), in dealflow coming from Universities, Research Centers, or other origins, in a very early stage even taking part in the settlement of the companies (or during the first years) and supporting the startups generating value, not only from a financial or legal perspective but also in fulfilling their strategic goals, thanks to our background investing in Health and also to the involvement of some of our Limited Partners, who are already players in the sector.

Clave Mayor was launched in 2002 in Pamplona (North of Spain) where we have our Headquarters. We currently have also branch offices in Valladolid and Valencia and we have managed during these 15 years more than a 100MM€.


COLUMBUS VENTURE PARTNERS, S.G.E.I.C., S.A.U is a Spanish Venture Capital Management Company focused in biotech and healthcare sector.

COLUMBUS VENTURE PARTNERS, S.G.E.I.C., S.A.U enhances the value of the most promising projects arising from renowned Spanish research institutions by guaranteeing that proper work takes places and ensuring the scientific, technological and commercial potential is understood before large capital is invested.

Columbus Venture Partners


At CriteriaCaixa we work hard every day to preserve and grow the assets generated by ”la Caixa” Banking Foundation for over a century. Our key priority is to provide the funding so that its Welfare Projects can continue to build a society that gives more opportunities to those most in need.

As Spain’s largest investment holding company, at CriteriaCaixa we have amassed a balanced portfolio over the years that combines significant shareholdings in strategic international sectors with a growing and diversified portfolio of investments. This ensures a recurring flow of dividends each year to be used for social welfare purposes.​

Each year, “la Caixa” Banking Foundation allocates more than 500 million euros to its social work, ultimately benefiting upwards of 11 million people through some 50,000 activities.​


EQT Partners has a track record of almost three decades of delivering consistent and attractive returns across multiple geographies, sectors and strategies. EQT invests in good companies with a mission to help them develop into great and sustainable companies.


Euronext is the leading European stock exchange with an unparallel reach across the continent with presence in 10 countries, +1400 listed companies and an active base of institutional investors from more than 50 countries. Euronext represents a unique platform for Tech companies with more than 500 listed companies, of which ca.110 are in the Life Science segment.

The European Investment Bank is the lending arm of the European Union. We are the biggest multilateral financial institution in the world and one of the largest providers of climate finance.


The European Investment Bank is the lending arm of the European Union. We are the biggest multilateral financial institution in the world and one of the largest providers of climate finance.

FORTY51 VENTURES, Switzerland

Started in Basel by three experienced Partners, Forty51 Ventures targets seed and early-stage investments. Biotech VC, company builder, helps early-stage companies get off the ground with force.


Fountain Healthcare Partners is a life science focused venture capital fund with EUR 300 million (USD 354 million) under management. Within the life science sector, specific areas of interest to Fountain include specialty pharma, medical devices, biotechnology and diagnostics. The firm deploys the majority of its capital in Europe, with the balance in the United States. Fountain’s main office is in Dublin, Ireland, with a second office in New York.

FUND+, Belgium

Fund+ is a Belgian venture capital firm that invests in innovative European Life Sciences companies developing drugs, medical devices and diagnostics, with a strong focus on patient-centric approaches and major unmet medical needs. With over €200M in assets under management, Fund+ has built a strong track record since 2015, investing in 13 portfolio companies with two major exits.  The fund is managed by a specialist team of seasoned life sciences professionals with healthcare industry, corporate finance and strategy consulting experience, supporting companies throughout their growth cycle.  The company aims to maintain a leading position in the Life Sciences sector, creating sustainable value for its shareholders and a tangible impact on society.


GENESIS Ventures is a tech transfer fund sized in2,5 M€ and managed by GENESIS Biomed, that invests in early stage research projects in the biomedical field, with the aim to accelerate their development and reach key value milestones to found the company and attract a first round of investment from other venture funds. The average ticket ranges from 25 to 100k. In our portfolio we have 12 invested companies: ABLE Human Motion, ADmit Therapeutics, CreatSens Health, Aortyx, Droplite, Mowoot, ELEM Bio, two pre-founded projects at IRYCIS and VHIR, NeuroHeal, Quality Pharma Medtech and Limnopharma.


GrayBella Capital is an investment partnership, investing in fast-growth technology and healthcare related companies in Europe


Inveready is a leading alternative asset manager in Spain – investing in early-stage VC, growth VC, venture Debt, strategic public equity, infrastructure, and private equity – providing financing solutions to companies throughout their life-cycle. Founded in 2008, Inveready counts on 150 active companies, +40 exits, and more than €600M of assets under management.


Invivo Capital Partners manages Invivo Ventures, a VC fund that has achieved a first closing of 40M€. It is focused on investing in early-stage companies in the healthcare sector: biotech, medtech, IVD and e-health projects. Our average ticket per company is around 0,5M€ and 2M€ (pre-seed and seed series) with the capacity to further invest through follow-ons in later stages of the best performing portfolio companies depending on the project and financial needs. Geographic focus is mainly Spain but other European companies are considered.

The team also manages Healthequity, SCR. since 2013, a VC fund also focused on the healthcare sector, which has already finished its investment period.

IPF PARTNERS, Switzerland

IPF Partners is a leading alternative financing provider focused on the healthcare sector. IPF Partners invests directly in emerging commercial stage pharma/biotech, medtech, diagnostics and IT healthcare companies.

IPF Partners provides customised low- to non-dilutive debt and equity financing to market leading healthcare companies.

The focus is on innovating products at commercial stage with a high potential in attractive markets. Typical deal size ranges from €5-25m+ over a 3- to 6-year duration.


Italfarmaco is a privately-held specialty pharmaceutical company, engaged in the development, manufacturing, marketing and sales of branded prescription and non-prescription pharmaceutical products, with budgeted 2022 sales of approximately $1Bn, 1800 sales reps, and a strong commitment to R&D through the investment of roughly 10% of its turnover.
Italfarmaco Group has a worlwide coverage with commercial operations across Europe, Middle East, Africa, LATAM and Vietnam through its own affiliates.
Italfarmaco’s products mainly addresses specializes Women´s Health, Cardiovascular, CNS, Musculoskeletal, Anemia, Supportive Care, Vitamins and Food Supplements.


Kaudal is a private equity financial structurer that believes in R&D and technology as fundamental drivers for the well-being and growth of our society. Our aim is to attract new investment that will help boost the development of innovative companies in Spain, strengthen the Spanish R&D ecosystem and facilitate the transfer of knowledge to the business world.

We are leaders in private financial structuring of R&D operations in Spain. We identify research and development projects and provide them with the funding necessary to be carried out. Since 2017, we have supported more than 70 projects for an investment volume of 100 million euros.


Keensight Capital is a European Growth Buyout investor with deep expertise in Healthcare and IT partnering with the management teams of fast growing and profitable companies providing capital, strategic guidance and operational support.

For 20 years, Keensight Capital’s team has leveraged their knowledge of investment and growth industries to invest for the long term in profitable companies with high growth potential and revenues in the range of €15 million to €250 million.


Kurma Partners is a key European venture capital group specialized in healthcare, with €470 million under management, with two dedicated franchises: Kurma Biofund focused on therapeutic (current active fund KBIII) and Kurma Diagnostics focused on diagnostic and digital health (current active fund Kurma Dx2).

M VENTURES, Netherlands

M Ventures is the corporate Venture Capital arm of Merck KgaA, Darmstadt Germany and takes an active role in company creation and investment.

M Ventures invests in innovative, early stage technology and biopharmaceutical companies with the potential to significantly impact Merck‘s business areas. The two core investment areas are technology and biotechnology, the technology mandate focuses on advanced chemistries, quantum computing, frontier tech and sustainability. The biotechnology mandate focuses on therapeutics and enabling technologies. Key areas of interest for therapeutics include immunology, oncology, immune-oncology and fertility.


Nara‘s purpose is to build value accelerating business transformation in impact sectors.

We support entrepreneurs who are changing the health paradigm. Just as information technologies have changed the world, biotechnology is going to change every aspect of our lives. We support innovation in biology and science. We invest in the convergence between technology and health.


Noso Capital is founded by a multidisciplinary team that pursues the goal of promoting companies in the long term and in the challenges of Industry 4.0, ESG and Globalization in the current economy. Is a pioneer in integrating technology experts and investing in companies that face important challenges in the global economic or technological environment or some extraordinary strategic, operational or financial situation.

Noso Capital’s philosophy is based on identifying high growth potentialities that require not only capital, but also and fundamentally professional support in management, providing value and results, with management, technological transformation, internationalization and adaptation to globalization, as levers of investment value creation. Technology is key and plays a very important role in our philosophy, as a lever to generate value and sustainability.


Novo Ventures is a life science venture capital investor, delivering knowledge, network, and capital to companies.

We strive to invest in companies that develop innovative drugs, medical devices and diagnostics. We focus on generating strong financial returns from our portfolio of venture companies. We invest in both private and public companies from an open evergreen fund. This funding structure enables us to take a long-term perspective.


We invest and boost life sciences innovation in a unique and comprehensive way. We work to make the best ideas grow, connecting them with a powerful ecosystem of means, experience and knowledge to turn them into real, efficient and successful projects.


Omnes is a leading Paris-based European investor in private equity and infrastructure. With €4 billion of assets under management, Omnes provides SMEs with the capital needed to finance growth. The firm has dedicated investment teams across three key areas: Venture Capital, Buyout & Growth Capital and Infrastructure. With more than 30 trade sales and nearly 15 IPOs in 20 years (including Novaled, Biovex, arGEN-X, Themis Bioscience and Direct Energie), Omnes Venture Capital team is a leading French player in financing innovative SMEs with dual expertise in the deep-tech and healthcare sectors.



Sodena is the instrument of the Government of Navarra for attracting and developing value-added business projects, contributing to regional development and the creation of quality employment.

Venture capital is Sodena’s main financial instrument for dealing with investment projects. Sodena is an active Venture Capital partner, which supports the management of its investee companies, is involved in decision-making on the board of directors and makes its extensive network of contacts available to the companies.


For almost two decades, XesGalicia has managed risk capital entities to support the growth of Galician companies. In this sense, our priorities focus on promoting the economic and industrial development and consolidation of Galicia, for which we have several financial instruments oriented to each type of company.


Ysios Capital is a leading Spanish venture capital firm that provides private equity financing to early- and mid-stage, highly innovative life science companies bringing life-changing treatments to patients, with a focus on indications with high unmet need. Our diverse international team in San Sebastián and Barcelona is driven by science, with the ambition to transform capital into medical breakthroughs. Ysios Capital was founded in 2008 and has over $450 million in assets under management through its three funds.


Venture Debt, Impact, ODS, SDG, Financing, Impact investing, ESG, SDG y Impact Venture Debt.

Born during the healthcare crisis. We are the reflection of change, a change in the way society produces and consumes, a change in the use of the available resources and a change to reduce inequalities. We want to be part of the change in order to achieve a sustainable future for all, face global challenges and set a legacy that will protect the planet, which will secure society’s prosperity and eradicate poverty. We want to help those businesses that share our vision and objectives through a flexible financing that allows founders to focus on their businesses and grow strong.

Previous Edition Participants (2022)

Ability Pharmaceuticals
AdBio Partners
Affirma Biotech
Airway Shield
Alira Health
Allinky Biopharma
Alta Life Sciences
Anquor Corporate Finance
Arthex Biotech
Asabys Partners
Ascent Business Advisors
AseBio - the Spanish Bioindustry Association
AurorA Science
Ayming España
Banca March
BeAble Capital
BHV Partners
BIO Seedbed Incubator
Biocat, la Fundació BioRegió de Catalunya
BioCrew Life Sciences
Biohope Scientific Solutions
Bioinnova Capital
Biokit S.A.
Biomedica Molecular Medicine
Bioseqs Genomics
BioSerentia Group
BME Growth
Business Angel - Miguel Ángel Pérez
Caixa Capital Risc
Capital Cell
Centre de Regulació Genòmica
Checkpoint Partners
Clave Capital
Clover Bioanalytical Software
Columbus Venture Partners
Consorcio de la Zona Especial Canaria
DISIT Biotech
Egile Corporation XXI
EQT Partners
European Investment Bank
FEDIT, Federación Española de Centros Tecnológicos
Forty51 Ventures
Fountain Healthcare Partners
Fundación Científica AECC
Fundación Tecnalia
Instituto de Investigación Sanitaria Fundación Jiménez Díaz
ICEX-Invest in Spain
Genesis Biomed
GrayBella Capital
Grifols Innovation and New Technology (GIANT)
HealthTech For Care
ICEX España Exportación e Inversiones
IDIAP Jordi Gol
Ikan Biotech
Immuno Coaching
Inhibitec Anticuerpos
Innoup Farma
Instituto Biomar
Integra Therapeutics
Invivo Capital Partners
IPF Partners
IQVIA Information
Italfarmaco Group
Janssen / Johnson & Johnson Innovation
Keensight Capital
Kurma Partners
Laminar Pharmaceuticals
M Ventures
Merck Life Science
MiMARK Diagnostics
MOA Biotech
Montajes Delsaz
Nara Capital
Neuroscience Innovative technologies (Neurostech)
Noso Capital
Novo Ventures
Nucaps Nanotechnology
Office of the Prime Minister of Spain
OILS4 Cure
Olavide Neuron STX
Omnes Capital
Oncoheroes Biosciences
Onechain Immunotherapeutics
Onena Medicines
Oniria Therapeutics
Oryzon Genomics
Ourcrowd Iberia
Palmeera Farms
Pricewaterhousecoopers Auditores
Protein Alternatives
PTS Granada
Sanifit Therapeutics
Spanish Ministry of Finance
SPR Health Investment
SunRock Biopharma
Taxbox Innovation
Valentia Ventures
Vivotecnia Research
Ysios Capital
Zubi Capital

Contact us